Health & Biotech
At Argent BioPharma, our mission is to revolutionize healthcare through pioneering innovation.
We go beyond traditional disease management by exploring the intricacies of the immune system and harnessing cutting-edge technologies in our research and development endeavors.
Through our commitment to advancing medical science, we aim to reshape the landscape of global healthcare by addressing unmet needs and offering hope to underserved populations worldwide.
Our vision encompasses becoming a leading biopharmaceutical company renowned for groundbreaking medical treatments. By embracing NanoPolyPharmacology, we strive to introduce impactful solutions that elevate standards within the life sciences industry. Our dedication extends to ensuring accessibility to innovative therapies for communities overlooked by conventional medical approaches, thereby bridging healthcare disparities on a global scale.
As we progress on this ambitious path, we invite you to follow our journey and be a part of a transformative shift in healthcare. At Argent BioPharma, we’re not just changing treatments; we’re changing lives.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Normal service is resuming for pot stocks as WSB buzz dies down
Health & Biotech
This cannabis ETF is still enjoying the wallstreetbets treatment
News
Last Orders: Small caps fall for 3rd day in worst loss this month
News
Closing Bell: Today’s Biggest Small Cap Movers on the ASX
Health & Biotech
MGC Pharma strikes exclusive world-wide product distribution agreement
Health & Biotech
Weed Week: Legal pot is a thing in Canberra — could NSW follow suit?
Health & Biotech
MGC Pharmaceuticals launches new clinical study into brain cancer treatment
Health & Biotech
MGC Pharma makes strong debut as London Stock Exchange’s first medicinal cannabis company
Health & Biotech
MGC Pharma is to become the first medicinal cannabis company to list on the London Stock Exchange
Stockhead TV
V-Con: Medical cannabis – green grass, green growth
Health & Biotech
MGC Pharma is soon to be admitted to the London Stock Exchange
Health & Biotech
MGC Pharma attracts $5m grant for its Malta-based production facility
Health & Biotech
MGC Pharmaceuticals confirms Phase II trial success for anti-inflammatory COVID treatment
News
10 at 10: These ASX stocks have found their voice this morning
Health & Biotech
Here’s how pot execs think the UN’s big cannabis shift can affect pot stocks in Australia
News
Last Orders: What you might have missed on the ASX today
News